These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 27557876)

  • 21. Predicting Major Bleeding in Ischemic Stroke Patients With Atrial Fibrillation.
    Hilkens NA; Algra A; Greving JP
    Stroke; 2017 Nov; 48(11):3142-3144. PubMed ID: 28931618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance of the HAS-BLED, ORBIT, and ATRIA Bleeding Risk Scores on a Cohort of 399 344 Hospitalized Patients With Atrial Fibrillation and Cancer: Data From the French National Hospital Discharge Database.
    Pastori D; Marang A; Bisson A; Herbert J; Lip GYH; Fauchier L
    J Am Heart Assoc; 2022 Dec; 11(23):e026388. PubMed ID: 36444864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
    Apostolakis S; Lane DA; Buller H; Lip GY
    Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Composite risk scores and composite endpoints in the risk prediction of outcomes in anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project.
    Banerjee A; Fauchier L; Bernard-Brunet A; Clementy N; Lip GY
    Thromb Haemost; 2014 Mar; 111(3):549-56. PubMed ID: 24452108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation.
    Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Marín F
    Sci Rep; 2017 Sep; 7(1):12066. PubMed ID: 28935868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incident Risk Factors and Major Bleeding in Patients with Atrial Fibrillation Treated with Oral Anticoagulants: A Comparison of Baseline, Follow-up and Delta HAS-BLED Scores with an Approach Focused on Modifiable Bleeding Risk Factors.
    Chao TF; Lip GYH; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Liao JN; Chung FP; Chen TJ; Chen SA
    Thromb Haemost; 2018 Apr; 118(4):768-777. PubMed ID: 29510426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial.
    Esteve-Pastor MA; Rivera-Caravaca JM; Shantsila A; Roldán V; Lip GYH; Marín F
    Thromb Haemost; 2017 Dec; 117(12):2261-2266. PubMed ID: 29212113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The predictive ability of the CHADS2 and CHA2DS2-VASc scores for bleeding risk in atrial fibrillation: the MAQI(2) experience.
    Barnes GD; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Froehlich JB; Kaatz S
    Thromb Res; 2014 Aug; 134(2):294-9. PubMed ID: 24929840
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Predictive value of four score systems on the bleeding risk in atrial fibrillation patients treated with dabigatran].
    Ding CC; Zhan BM; Zhou W; Li MH; Hu LH; Bao HH; Cheng XS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Sep; 48(9):748-752. PubMed ID: 32957757
    [No Abstract]   [Full Text] [Related]  

  • 30. The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion.
    García-Fernández A; Marín F; Roldán V; Galcerá-Jornet E; Martínez-Martínez JG; Valdés M; Sogorb F; Lip GY
    Int J Cardiol; 2016 Aug; 217():42-8. PubMed ID: 27179207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of HAS-BLED and HAS-BED Versus CHADS
    Poli D; Antonucci E; Pengo V; Testa S; Palareti G
    Am J Cardiol; 2017 Apr; 119(7):1012-1016. PubMed ID: 28237286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
    Lip GY; Frison L; Halperin JL; Lane DA
    J Am Coll Cardiol; 2011 Jan; 57(2):173-80. PubMed ID: 21111555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?
    Esteve-Pastor MA; García-Fernández A; Macías M; Sogorb F; Valdés M; Roldán V; Muñiz J; Badimon L; Roldán I; Bertomeu-Martínez V; Cequier Á; Lip GY; Anguita M; Marín F;
    Circ J; 2016 Sep; 80(10):2102-8. PubMed ID: 27557850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).
    Steinberg BA; Shrader P; Kim S; Thomas L; Fonarow GC; Ansell J; Kowey PR; Singer DE; Gersh BJ; Mahaffey KW; Peterson ED; Piccini JP;
    Am Heart J; 2016 Nov; 181():145-152. PubMed ID: 27823686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
    Ruiz-Nodar JM; Marín F; Roldán V; Valencia J; Manzano-Fernández S; Caballero L; Hurtado JA; Sogorb F; Valdés M; Lip GY
    Circ Cardiovasc Interv; 2012 Aug; 5(4):459-66. PubMed ID: 22787018
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy.
    Capodanno D; Rossini R; Musumeci G; Lettieri C; Senni M; Valsecchi O; Angiolillo DJ; Lip GY
    Int J Cardiol; 2015 Nov; 199():319-25. PubMed ID: 26241637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of HAS-BLED with other risk models for predicting the bleeding risk in anticoagulated patients with atrial fibrillation: A PRISMA-compliant article.
    Zeng J; Yu P; Cui W; Wang X; Ma J; Zeng C
    Medicine (Baltimore); 2020 Jun; 99(25):e20782. PubMed ID: 32569222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative validation of HAS-BLED, GARFIELD-AF and ORBIT bleeding risk scores in Asian people with atrial fibrillation treated with oral anticoagulant: A report from the COOL-AF registry.
    Chichareon P; Winijkul A; Lip GYH; Krittayaphong R
    Br J Clin Pharmacol; 2023 Aug; 89(8):2472-2482. PubMed ID: 36942465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.
    Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Held C; Hylek EM; Lopes RD; Siegbahn A; Yusuf S; Granger CB; Wallentin L;
    Lancet; 2016 Jun; 387(10035):2302-2311. PubMed ID: 27056738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive ability of HAS-BLED, HEMORR2HAGES, and ATRIA bleeding risk scores in patients with atrial fibrillation: Methodological issues of prediction models.
    Sani M; Ayubi E; Mansori K; Khazaei S
    Int J Cardiol; 2016 Nov; 222():949. PubMed ID: 27526365
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.